CRVS
Price
$6.08
Change
+$0.17 (+2.88%)
Updated
Sep 9, 12:41 PM (EDT)
Capitalization
439.63M
51 days until earnings call
RZLT
Price
$8.17
Change
+$0.22 (+2.77%)
Updated
Sep 9, 01:18 PM (EDT)
Capitalization
691.62M
2 days until earnings call
Interact to see
Advertisement

CRVS vs RZLT

Header iconCRVS vs RZLT Comparison
Open Charts CRVS vs RZLTBanner chart's image
Corvus Pharmaceuticals
Price$6.08
Change+$0.17 (+2.88%)
Volume$500
Capitalization439.63M
Rezolute
Price$8.17
Change+$0.22 (+2.77%)
Volume$13.59K
Capitalization691.62M
CRVS vs RZLT Comparison Chart in %
Loading...
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RZLT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRVS vs. RZLT commentary
Sep 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRVS is a StrongBuy and RZLT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 09, 2025
Stock price -- (CRVS: $5.90 vs. RZLT: $7.95)
Brand notoriety: CRVS and RZLT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRVS: 155% vs. RZLT: 77%
Market capitalization -- CRVS: $439.63M vs. RZLT: $691.62M
CRVS [@Biotechnology] is valued at $439.63M. RZLT’s [@Biotechnology] market capitalization is $691.62M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.34B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRVS’s FA Score shows that 0 FA rating(s) are green whileRZLT’s FA Score has 0 green FA rating(s).

  • CRVS’s FA Score: 0 green, 5 red.
  • RZLT’s FA Score: 0 green, 5 red.
According to our system of comparison, both CRVS and RZLT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRVS’s TA Score shows that 5 TA indicator(s) are bullish while RZLT’s TA Score has 4 bullish TA indicator(s).

  • CRVS’s TA Score: 5 bullish, 4 bearish.
  • RZLT’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, both CRVS and RZLT are a good buy in the short-term.

Price Growth

CRVS (@Biotechnology) experienced а +2.79% price change this week, while RZLT (@Biotechnology) price change was +11.66% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.04%. For the same industry, the average monthly price growth was +10.49%, and the average quarterly price growth was +34.78%.

Reported Earning Dates

CRVS is expected to report earnings on Oct 30, 2025.

RZLT is expected to report earnings on Sep 11, 2025.

Industries' Descriptions

@Biotechnology (+1.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RZLT($692M) has a higher market cap than CRVS($440M). RZLT YTD gains are higher at: 62.245 vs. CRVS (10.280). CRVS has higher annual earnings (EBITDA): -35.45M vs. RZLT (-77.12M). RZLT has more cash in the bank: 86.9M vs. CRVS (74.4M). CRVS has less debt than RZLT: CRVS (1.08M) vs RZLT (1.78M). CRVS (0) and RZLT (0) have equivalent revenues.
CRVSRZLTCRVS / RZLT
Capitalization440M692M64%
EBITDA-35.45M-77.12M46%
Gain YTD10.28062.24517%
P/E RatioN/AN/A-
Revenue00-
Total Cash74.4M86.9M86%
Total Debt1.08M1.78M61%
FUNDAMENTALS RATINGS
CRVS vs RZLT: Fundamental Ratings
CRVS
RZLT
OUTLOOK RATING
1..100
6529
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
55
Fair valued
PROFIT vs RISK RATING
1..100
82100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
3735
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
1285

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RZLT's Valuation (55) in the null industry is in the same range as CRVS (59) in the Pharmaceuticals Major industry. This means that RZLT’s stock grew similarly to CRVS’s over the last 12 months.

CRVS's Profit vs Risk Rating (82) in the Pharmaceuticals Major industry is in the same range as RZLT (100) in the null industry. This means that CRVS’s stock grew similarly to RZLT’s over the last 12 months.

CRVS's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as RZLT (99) in the null industry. This means that CRVS’s stock grew similarly to RZLT’s over the last 12 months.

RZLT's Price Growth Rating (35) in the null industry is in the same range as CRVS (37) in the Pharmaceuticals Major industry. This means that RZLT’s stock grew similarly to CRVS’s over the last 12 months.

CRVS's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as RZLT (100) in the null industry. This means that CRVS’s stock grew similarly to RZLT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRVSRZLT
RSI
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
74%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
89%
MACD
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 5 days ago
88%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
N/A
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
81%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RZLT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HGORX64.400.53
+0.83%
Hartford Growth Opportunities R3
TEMHX9.360.07
+0.75%
Nuveen Emerging Markets Eq I
ADGZX28.300.11
+0.39%
AB Core Opportunities Z
FERAX12.35N/A
N/A
First Eagle Global Real Assets A
GSBGX23.46N/A
N/A
GMO Small Cap Quality Fund Class VI

CRVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been loosely correlated with SYRE. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVS jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
-4.22%
SYRE - CRVS
42%
Loosely correlated
-2.18%
TERN - CRVS
39%
Loosely correlated
+0.83%
IPSC - CRVS
37%
Loosely correlated
+1.11%
RZLT - CRVS
36%
Loosely correlated
-0.63%
AMLX - CRVS
34%
Loosely correlated
+2.35%
More

RZLT and

Correlation & Price change

A.I.dvisor indicates that over the last year, RZLT has been loosely correlated with RLAY. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if RZLT jumps, then RLAY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RZLT
1D Price
Change %
RZLT100%
-0.63%
RLAY - RZLT
47%
Loosely correlated
-1.46%
XNCR - RZLT
45%
Loosely correlated
-1.64%
CRNX - RZLT
43%
Loosely correlated
-1.32%
SYRE - RZLT
42%
Loosely correlated
-2.18%
ATYR - RZLT
41%
Loosely correlated
-2.67%
More